Literature DB >> 18761444

Inhibition of class A beta-lactamases by carbapenems: crystallographic observation of two conformations of meropenem in SHV-1.

Michiyosi Nukaga1, Christopher R Bethel, Jodi M Thomson, Andrea M Hujer, Anne Distler, Vernon E Anderson, James R Knox, Robert A Bonomo.   

Abstract

Carbapenem antibiotics are often the "last resort" in the treatment of infections caused by bacteria resistant to penicillins and cephalosporins. To understand why meropenem is resistant to hydrolysis by the SHV-1 class A beta-lactamase, the atomic structure of meropenem inactivated SHV-1 was solved to 1.05 A resolution. Two conformations of the Ser70 acylated intermediate are observed in the SHV-1-meropenem complex; the meropenem carbonyl oxygen atom of the acyl-enzyme is in the oxyanion hole in one conformation, while in the other conformation it is not. Although the structures of the SHV-1 apoenzyme and the SHV-1-meropenem complex are very similar (0.29 A rmsd for Calpha atoms), the orientation of the conserved Ser130 is different. Notably, the Ser130-OH group of the SHV-1-meropenem complex is directed toward Lys234Nz, while the Ser130-OH of the apo enzyme is oriented toward the Lys73 amino group. This altered position may affect proton transfer via Ser130 and the rate of hydrolysis. A most intriguing finding is the crystallographic detection of protonation of the Glu166 known to be involved in the deacylation mechanism. The critical deacylation water molecule has an additional hydrogen-bonding interaction with the OH group of meropenem's 6alpha-1 R-hydroxyethyl substituent. This interaction may weaken the nucleophilicity and/or change the direction of the lone pair of electrons of the water molecule and result in poor turnover of meropenem by the SHV-1 beta-lactamase. Using timed mass spectrometry, we further show that meropenem is covalently attached to SHV-1 beta-lactamase for at least 60 min. These observations explain key properties of meropenem's ability to resist hydrolysis by SHV-1 and lead to important insights regarding future carbapenem and beta-lactamase inhibitor design.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18761444      PMCID: PMC4071967          DOI: 10.1021/ja7111146

Source DB:  PubMed          Journal:  J Am Chem Soc        ISSN: 0002-7863            Impact factor:   15.419


  37 in total

Review 1.  What's new in the antibiotic pipeline.

Authors:  V J Lee; G H Miller; M Yagisawa
Journal:  Curr Opin Microbiol       Date:  1999-10       Impact factor: 7.934

Review 2.  How beta-lactamases have driven pharmaceutical drug discovery. From mechanistic knowledge to clinical circumvention.

Authors:  K Bush; S Mobashery
Journal:  Adv Exp Med Biol       Date:  1998       Impact factor: 2.622

3.  XtalView/Xfit--A versatile program for manipulating atomic coordinates and electron density.

Authors:  D E McRee
Journal:  J Struct Biol       Date:  1999 Apr-May       Impact factor: 2.867

4.  Structure of the SHV-1 beta-lactamase.

Authors:  A P Kuzin; M Nukaga; Y Nukaga; A M Hujer; R A Bonomo; J R Knox
Journal:  Biochemistry       Date:  1999-05-04       Impact factor: 3.162

Review 5.  Expanding the model: anisotropic displacement parameters in protein structure refinement.

Authors:  E A Merritt
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  1999-06

6.  Inhibition of the SHV-1 beta-lactamase by sulfones: crystallographic observation of two reaction intermediates with tazobactam.

Authors:  A P Kuzin; M Nukaga; Y Nukaga; A Hujer; R A Bonomo; J R Knox
Journal:  Biochemistry       Date:  2001-02-13       Impact factor: 3.162

7.  Crystal structures of the class D beta-lactamase OXA-13 in the native form and in complex with meropenem.

Authors:  L Pernot; F Frénois; T Rybkine; G L'Hermite; S Petrella; J Delettré; V Jarlier; E Collatz; W Sougakoff
Journal:  J Mol Biol       Date:  2001-07-20       Impact factor: 5.469

8.  GES-2, a class A beta-lactamase from Pseudomonas aeruginosa with increased hydrolysis of imipenem.

Authors:  L Poirel; G F Weldhagen; T Naas; C De Champs; M G Dove; P Nordmann
Journal:  Antimicrob Agents Chemother       Date:  2001-09       Impact factor: 5.191

9.  Mutagenesis of amino acid residues in the SHV-1 beta-lactamase: the premier role of Gly238Ser in penicillin and cephalosporin resistance.

Authors:  A M Hujer; K M Hujer; R A Bonomo
Journal:  Biochim Biophys Acta       Date:  2001-05-05

10.  Noncovalent interaction energies in covalent complexes: TEM-1 beta-lactamase and beta-lactams.

Authors:  Xiaojun Wang; George Minasov; Brian K Shoichet
Journal:  Proteins       Date:  2002-04-01
View more
  45 in total

1.  Overcoming an Extremely Drug Resistant (XDR) Pathogen: Avibactam Restores Susceptibility to Ceftazidime for Burkholderia cepacia Complex Isolates from Cystic Fibrosis Patients.

Authors:  Krisztina M Papp-Wallace; Scott A Becka; Elise T Zeiser; Nozomi Ohuchi; Maria F Mojica; Julian A Gatta; Monica Falleni; Delfina Tosi; Elisa Borghi; Marisa L Winkler; Brigid M Wilson; John J LiPuma; Michiyoshi Nukaga; Robert A Bonomo
Journal:  ACS Infect Dis       Date:  2017-03-30       Impact factor: 5.084

2.  Structures of the Michaelis complex (1.2 Å) and the covalent acyl intermediate (2.0 Å) of cefamandole bound in the active sites of the Mycobacterium tuberculosis β-lactamase K73A and E166A mutants.

Authors:  Lee W Tremblay; Hua Xu; John S Blanchard
Journal:  Biochemistry       Date:  2010-10-25       Impact factor: 3.162

3.  Insights into β-lactamases from Burkholderia species, two phylogenetically related yet distinct resistance determinants.

Authors:  Krisztina M Papp-Wallace; Magdalena A Taracila; Julian A Gatta; Nozomi Ohuchi; Robert A Bonomo; Michiyoshi Nukaga
Journal:  J Biol Chem       Date:  2013-05-08       Impact factor: 5.157

4.  Influence of substrates and inhibitors on the structure of Klebsiella pneumoniae carbapenemase-2.

Authors:  Ben A Shurina; Richard C Page
Journal:  Exp Biol Med (Maywood)       Date:  2019-06-04

5.  Excess positional mutual information predicts both local and allosteric mutations affecting beta lactamase drug resistance.

Authors:  George A Cortina; Peter M Kasson
Journal:  Bioinformatics       Date:  2016-07-27       Impact factor: 6.937

6.  Biochemical and structural characterization of Mycobacterium tuberculosis beta-lactamase with the carbapenems ertapenem and doripenem.

Authors:  Lee W Tremblay; Fan Fan; John S Blanchard
Journal:  Biochemistry       Date:  2010-05-04       Impact factor: 3.162

7.  Substitutions at position 105 in SHV family β-lactamases decrease catalytic efficiency and cause inhibitor resistance.

Authors:  Mei Li; Benjamin C Conklin; Magdalena A Taracila; Rebecca A Hutton; Marion J Skalweit
Journal:  Antimicrob Agents Chemother       Date:  2012-08-20       Impact factor: 5.191

8.  Enhancing resistance to cephalosporins in class C beta-lactamases: impact of Gly214Glu in CMY-2.

Authors:  Andrea Endimiani; Yohei Doi; Christopher R Bethel; Magdalena Taracila; Jennifer M Adams-Haduch; Alexandra O'Keefe; Andrea M Hujer; David L Paterson; Marion J Skalweit; Malcolm G P Page; Sarah M Drawz; Robert A Bonomo
Journal:  Biochemistry       Date:  2010-02-09       Impact factor: 3.162

9.  The role of a second-shell residue in modifying substrate and inhibitor interactions in the SHV beta-lactamase: a study of ambler position Asn276.

Authors:  Sarah M Drawz; Christopher R Bethel; Kristine M Hujer; Kelly N Hurless; Anne M Distler; Emilia Caselli; Fabio Prati; Robert A Bonomo
Journal:  Biochemistry       Date:  2009-06-02       Impact factor: 3.162

10.  Inhibition of the class C beta-lactamase from Acinetobacter spp.: insights into effective inhibitor design.

Authors:  Sarah M Drawz; Maja Babic; Christopher R Bethel; Magda Taracila; Anne M Distler; Claudia Ori; Emilia Caselli; Fabio Prati; Robert A Bonomo
Journal:  Biochemistry       Date:  2010-01-19       Impact factor: 3.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.